Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H17F2N5O3S |
Molecular Weight | 409.41 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(N)=N[C@@](C)(CS1(=O)=O)C2=C(F)C=CC(NC(=O)C3=NC=C(F)C=C3)=C2
InChI
InChIKey=YHYKUSGACIYRML-KRWDZBQOSA-N
InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
Molecular Formula | C17H17F2N5O3S |
Molecular Weight | 409.41 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Verubecestat (MK 8931) is a potentially first-in-class, potent β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor being developed by Merck. Verubecestat (MK-8931) is a selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of Aβ40, Aβ42, and sAPPβ (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys. Verubecestat was under investigation for the treatment of Alzheimer's disease, prodromal Alzheimer's disease, and amnestic mild cognitive impairment. In November 2013, Merck began the APECS trial in 1,500 participants with prodromal AD, aka mild cognitive impairment due to AD (aMCI). These patients have measurable cognitive deficits and a positive PET scan with the newly FDA-approved amyloid tracer flutemetamol, but are not functionally impaired. APECS compared 12 and 40 mg once-daily doses to placebo; treatment was to last for two years. APECS usef change from baseline on the Clinical Dementia Rating Sum of Boxes (CDR-SB), a continuous measure, as its primary outcome. Secondary outcomes evaluated a range of newer measures, including a cognitive composite, CSF tau, brain imaging of hippocampal volume and amyloid load, and others. This trial was being conducted in more than 90 locations worldwide; it completed enrollment in November 2016 and was expected to complete data collection for its primary outcome in 2019. In February 2018, APECS was discontinued and Merck no longer listed verubecestat in its research pipeline. APECS participants on 40 mg verubecestat scored worse than the placebo group on the CDR-SB and ADAS-Cog13 starting at 13 weeks. The effect was small and did not progress over time. The 12 mg treatment group also performed slightly worse than controls, with the difference reaching significance at scattered time points.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4822 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23412139 |
7.8 nM [Ki] |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
125.26 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
585.11 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3447.82 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
439.52 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
602.22 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1050.06 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
666.71 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.95 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.84 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
46.27 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.47 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.17 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
13.33 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
8.38 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.27 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
19.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30347431/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
VERUBECESTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45% |
unknown, unknown |
VERUBECESTAT plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.alzforum.org/therapeutics/verubecestat
12, 40, or 60 mg/day of Verubecestat (MK 8931) given as once-daily tablets to placebo in people with mild to moderate AD.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:24:16 GMT 2025
by
admin
on
Tue Apr 01 16:24:16 GMT 2025
|
Record UNII |
J1I0P6WT7T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
||
|
NCI_THESAURUS |
C1509
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152868
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
SUB185177
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
1286770-55-5
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
100000170947
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
J1I0P6WT7T
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
Verubecestat
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
51352361
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL3301601
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
10028
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
1613380-81-6
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
SUPERSEDED | |||
|
DTXSID301020622
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
BC-75
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY | |||
|
DB12285
Created by
admin on Tue Apr 01 16:24:16 GMT 2025 , Edited by admin on Tue Apr 01 16:24:16 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> NON-INDUCER |
IC50
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
CELLULAR ASSAY
IC50
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> NON-INDUCER |
IC50
|
||
|
OFF-TARGET->INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |